Reports
Sale
Global Upper Respiratory Tract Infection Treatment Market Share, Size, Analysis, Forecast: By Type: Antibiotics, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) And Nasal Decongestants, Others; By Route of Administration: Oral, Nasal, Parenteral; By Distribution Channel; Market Dynamics; Regional Analysis; Supplier Landscape; 2024-2032
Global Upper Respiratory Tract Infection Treatment Market Outlook
The global upper respiratory tract infection treatment market size attained a value of USD 1.75 billion in 2023. The market is likely to grow at a CAGR of 3.55% during the forecast period of 2024-2032. With this growth rate, the market is anticipated to attain a value of USD 2.40 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Upper Respiratory Tract Infection Treatment Market: Introduction and Insights
An upper respiratory tract infection (URTI) is an illness, which is the result of an acute infection involving a person’s upper respiratory tract like the nose, sinuses, pharynx, or larynx. The infection commonly includes nasal obstruction, sore throat, tonsillitis, pharyngitis, laryngitis, otitis media, and the common cold. This can be treated using various drugs, targeting disease-causing pathogens like bacteria and viruses.
The signs and symptoms of the condition include fever, cough, runny nose, hoarse voice, fatigue, vomiting, unconsciousness, difficulty in breathing, retractions, especially in children, and stridor, among others. While the symptoms usually get better in one to two weeks, in some cases the condition might get worse if the symptoms do not subside within this timeline. In worst case scenario, the infection might lead to bronchitis or pneumonia.
Upper respiratory tract infection can affect anyone, but some people are more prone to the condition, especially children. Children are at a higher risk of catching the infection since the possibility of transmission is much higher. Children do no follow regular hygiene habits, like washing hands, and are more likely to carry the germs in their hands and put their fingers in their mouth, nose, and/or eyes, enabling the germs to enter the body. Other than children, people with lung or heart disorders are also vulnerable to the condition. Weak immune system also makes people more prone to upper respiratory tract infection.
Upper Respiratory Tract Infection Treatment Market Segmentations
The market can be categorised into segments like type, route of administration, distribution channel, and major regions.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Type
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) And Nasal Decongestants
- Others
Market Breakup by Route of Administration
- Oral
- Nasal
- Parenteral
Market by Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Others
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Upper Respiratory Tract Infection Treatment Market Analysis
The growing incidence of upper respiratory tract infections, the development of new drugs, and the increasing demand for over-the-counter drugs is aiding the growth of the upper respiratory tract infection treatment market globally. With the advancement in technology and development in the treatment of upper respiratory tract infection, the market is witnessing an increased growth. Further, the growing awareness regarding the treatment and the rising disposable income, especially in emerging economies, are expected to drive the industry growth over the forecast period.
The antibiotics segment, among other types, dominated the global market in 2023, owing to its easy availability and effective results. Region-wise, while North America accounted for the highest share in the market in 2023, the Asia Pacific region is expected to grow at the fastest rate over the forecast period owing to the growing population and increased expenditure on health care services in the region.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
The report presents a detailed analysis of the following key players in the global upper respiratory tract infection treatment market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Cipla Limited
- Lupin Limited
- Merck & Co., Inc.
- Alcon, Inc.
- Teva Pharmaceuticals
- Sandoz, Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Upper Respiratory Tract Infection Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Upper Respiratory Tract Infection Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Upper Respiratory Tract Infection Epidemiology (2016-2031)
5.3 Europe Upper Respiratory Tract Infection Epidemiology (2016-2031)
5.4 Asia-Pacific Upper Respiratory Tract Infection Epidemiology (2016-2031)
5.5 Latin America Upper Respiratory Tract Infection Epidemiology (2016-2031)
5.6 Middle East & Africa Upper Respiratory Tract Infection Epidemiology (2016-2031)
6 Global Upper Respiratory Tract Infection Treatment Market Overview
6.1 Global Upper Respiratory Tract Infection Treatment Market Historical Value (2017-2023)
6.2 Global Upper Respiratory Tract Infection Treatment Market Forecast Value (2024-2032)
7 Global Upper Respiratory Tract Infection Treatment Market Landscape
7.1 Upper Respiratory Tract Infection Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Upper Respiratory Tract Infection Treatment: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by Distribution Channel
8 Upper Respiratory Tract Infection Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Upper Respiratory Tract Infection Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Upper Respiratory Tract Infection Treatment Market Segmentation
11.1 Global Upper Respiratory Tract Infection Treatment Market by Type
11.1.1 Market Overview
11.1.2 Antibiotics
11.1.3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) And Nasal Decongestants
11.1.4 Others
11.2 Global Upper Respiratory Tract Infection Treatment Market by Route of Administration
11.2.1 Market Overview
11.2.2 Oral
11.2.3 Nasal
11.2.4 Parenteral
11.3 Global Upper Respiratory Tract Infection Treatment Market by Distribution Channel
11.3.1 Market Overview
11.3.2 Hospital Pharmacies
11.3.3 Retail Pharmacies
11.3.4 Online Pharmacies
11.3.5 Others
11.4 Global Upper Respiratory Tract Infection Treatment Market by Region
11.4.1 Market Overview
11.4.2 North America
11.4.3 Europe
11.4.4 Asia Pacific
11.4.5 Latin America
11.4.6 Middle East and Africa
12 North America Upper Respiratory Tract Infection Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Upper Respiratory Tract Infection Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Upper Respiratory Tract Infection Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Upper Respiratory Tract Infection Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Upper Respiratory Tract Infection Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 GlaxoSmithKline plc
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 F. Hoffmann-La Roche Ltd
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Pfizer Inc.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Cipla Limited
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Lupin Limited
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Merck & Co., Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Alcon, Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Teva Pharmaceuticals
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Sandoz, Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
24 Upper Respiratory Tract Infection Treatment - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market size attained a value of USD 1.75 billion in 2023, driven by the rising prevalence of lung disorders.
The market is likely to grow at a CAGR of 3.55% during the forecast period of 2024-2032 to attain a value of USD 2.40 billion by 2032.
The major drivers of the market include the growing incidence of upper respiratory tract infections, development of new drugs, growing awareness regarding the treatment, rising disposable income, and advancement in technology.
They key trends in the market include the rise in the demand for and availability of over-the-counter drugs, and the advent of biologics.
The major regional markets include North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
The types can be divided into nonsteroidal anti-inflammatory drugs (NSAIDs) And nasal decongestants, among others.
The routes of administration include oral, nasal, and parenteral routes.
The distribution channels in the market include hospital pharmacies and online pharmacies, among others.
The key players in the market include GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer Inc., Cipla Limited, Lupin Limited, Merck & Co., Inc., Alcon, Inc., Teva Pharmaceuticals, and Sandoz, Inc., among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5999
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 7999
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9999
$5999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER